$33.37 -1.17 (-3.39%) Medicines Co - NASDAQ

Dec. 7, 2016 | 04:00 PM

Quotes

  1. Quotes

  2. Charts

  3. Analysis

  4. Options

  5. Historical



Last Trade: 33.37
Trade Time: Dec 07 04:00 PM Eastern Daylight Time
Change: -1.17 (-3.39%)
Prev Close: 34.54
Open: 34.03
Bid: 33.37
Ask: 33.38
  1. No results found.
  1. Biotechs Aerie, Medicines Co., Tesaro Could Rocket, Or Be Bought: RBC

    Investors Business Daily | Dec. 1, 2016 | 14:14PM EST
  2. Biotech Stocks Soar on Election Results, Gilead HBV Drug Approved

    TalkMarkets | Nov. 16, 2016 | 15:30PM EST
  3. On The Fly: After Hours Movers - 11/8

    TalkMarkets | Nov. 8, 2016 | 02:44AM EST
  4. Biotech Stock Roundup: Ariad Down On Drug Pricing Tweet, Regeneron Study On Clinical Hold

    TalkMarkets | Oct. 19, 2016 | 14:27PM EST
  5. Jefferies Sees 'Attractive Buying Opportunities' In Biotech

    TalkMarkets | Oct. 18, 2016 | 10:16AM EST
  6. Battleground: Alnylam Plunges After Revusiran Pulled, But Some See Opportunity

    TalkMarkets | Oct. 6, 2016 | 19:50PM EST
  7. Medicines Co. up on sale talk

    IBD | Jan. 20, 2016 | 18:40PM EST
  8. Mid-Afternoon Market Update: Dow Falls Over 400 Points; Advanced Micro Devices Shares Drop After Disappointing Guidance

    Benzinga | Jan. 20, 2016 | 14:48PM EST
  9. Medicines Company Spikes On Report Of Possible Sale

    IBD | Jan. 20, 2016 | 12:59PM EST
  10. Medicines Co Up For Sale? Bloomberg Info Comes Day After Benzinga Report; Companies Decline Comment

    Benzinga | Jan. 20, 2016 | 10:56AM EST
  11. The Medicines Company Announces Investigational Lipid Modulating Agent, MDCO-216, Phase 1 Data Published in European Heart Journal- Cardiovascular Pharmacotherapy

    Benzinga | Dec. 14, 2015 | 20:10PM EST
  12. Breakaway Gaps By Stocks Can Be Scary But Profitable

    IBD | Dec. 3, 2015 | 17:58PM EST
  13. Benzinga's Top Initiations

    Benzinga | Nov. 4, 2015 | 10:28AM EST
  14. Lilly Kills 'High Risk/High Reward' Cholesterol Drug

    IBD | Oct. 12, 2015 | 09:42AM EST
  15. The Medicines Company Announces BARDA Exercises Next Option on Contract for Support of the Development of CARBAVANCE® (meropenem/RPX7009) for Drug-Resistant Gram-Negative Pathogens

    Benzinga | Oct. 1, 2015 | 06:03AM EST
Trading Center